John R. Bales

John R. Bales

Auto-generated profile, based on publicly available information

John R. Bales

Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114 USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in The Spine Journal
Verified
Journal Article
Closed access
ALAmanda Lans
Amanda Lans
JBJohn R. Bales
John R. Bales
DTDaniel G. Tobert
Daniel G. Tobert
LRLaura P. Rossi
Laura P. Rossi
JVJorrit-Jan Verlaan
Jorrit-Jan Verlaan
JSJoseph H. Schwab
Joseph H. Schwab

21 December 2022 in The Spine Journal
Verified
Journal Article
Closed access
ALAmanda Lans
Amanda Lans
JBJohn R. Bales
John R. Bales
Mitchell S. FourmanMitchell S. Fourman
Mitchell S. Fourman
DTDaniel G. Tobert
Daniel G. Tobert
JVJorrit-Jan Verlaan
Jorrit-Jan Verlaan
JSJoseph H. Schwab
Joseph H. Schwab

2 May 2022 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
VVVinayak Venkataraman
Vinayak Venkataraman
JBJohn R Bales
John R Bales
JSJessie Signorelli
Jessie Signorelli
GHGabriela S Hobbs
Gabriela S Hobbs
Introduction: In this study, we aim to determine the risk of bleeding or thrombosis with concurrent use of tyrosine kinase inhibitors (TKIs) used to treat CML, and serotonin reuptake inhibitors (SSRIs). Methods: We conducted a retrospective cohort study of patients with CP-CML cared for at Massachusetts General Hospital (MGH) between April 2016 to February 2021. Participants were included if diagnosed with CP-CML and began TKI treatment (imatinib, dasatinib, nilotinib, bosutinib, or ponatinib) after April 2016. Results: One hundred patients were evaluated, eighty of whom were taking TKIs only (median age 55, 40% female), and twenty were taking TKI and SSRI concomitantly (median age 53.5, 55% female). Baseline demographics between these groups were similar across all variables. Patients in the TKI only group had 9 bleeding events and 3 thrombotic events. Patients in the combination group had 6 bleeding events and 1 thrombotic event. There was no difference between overall rates of major bleeding (4% v. 10%, p = 0.26) or thrombotic events (4% v. 5%, p = 1). However, patients in the combination group were more likely to have major intracranial bleeding events (0% v. 10%, p = 0.04), and there was a trend to significance for minor bleeding events (7.5% v. 20%, p = 0.11). Conclusions: Concomitant use of TKIs and SSRIs does not appear to increase the total risk of bleeding or thrombotic events compared to patients on TKIs only. However, concomitant use of TKIs and SSRIs may increase risk of intracranial bleeding. Further work is needed to fully assess this risk.